Bank of Montreal Can Raises Stock Position in AbbVie Inc. $ABBV

Bank of Montreal Can raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,975,374 shares of the company’s stock after acquiring an additional 177,720 shares during the quarter. Bank of Montreal Can owned approximately 0.17% of AbbVie worth $688,918,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ABBV. Brighton Jones LLC lifted its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its holdings in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares in the last quarter. Penserra Capital Management LLC grew its holdings in AbbVie by 500.0% during the 2nd quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock valued at $159,000 after buying an additional 720 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of AbbVie during the second quarter valued at approximately $581,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $227.75 on Tuesday. The stock has a 50 day moving average price of $224.66 and a 200 day moving average price of $224.33. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $402.70 billion, a P/E ratio of 96.50, a P/E/G ratio of 0.80 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company posted $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABBV. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday. Evercore decreased their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Finally, Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) showed clinically meaningful weight loss (~7.8–9.8% at week 12/13) with favorable tolerability, supporting continued development as a non‑incretin obesity option. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive Phase 3 AFFIRM topline results for risankizumab (SKYRIZI) in Crohn’s disease point to label expansion and incremental sales upside for an already commercialized franchise. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Analyst support: J.P. Morgan reiterated a Buy rating, which reinforces investor confidence in AbbVie’s mix of cash flow, dividend, and pipeline optionality. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Positive Sentiment: Industry coverage notes ABBV‑295’s competitive profile vs. GLP‑1/GIP approaches, which could drive differentiated positioning if later‑stage data hold up. AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
• Neutral Sentiment: Analyst / media attention (Zacks, Yahoo) is elevating interest in ABBV as a momentum/dividend name, but these are background supports rather than immediate catalysts. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Broader write‑ups synthesize recent trial updates into AbbVie’s valuation/growth outlook — useful context but not a single-day catalyst. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: Despite positive ABBV‑295 numbers, shares fell after the readout — investors may be disappointed relative to expectations versus GLP‑1/GIP therapies or are focusing on pathway uncertainty and commercialization risk. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s drug — a health‑economics review can lead to pricing/reimbursement pressures if cost‑effectiveness is questioned. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Corporate/financial items: an SVP sold about $1.22M of stock and AbbVie has tied roughly $350M to the amylin program — insider selling and program commitments can be read as modest near‑term negatives for sentiment or cash deployment. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock AbbVie ties $350m amylin bet to almost 10% weight loss after 12 weeks

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.